key: cord-0921647-o7b76fqc
authors: Kobiyama, Kouji; Imai, Masaki; Jounai, Nao; Nakayama, Misako; Hioki, Kou; Iwatsuki-Horimoto, Kiyoko; Yamayoshi, Seiya; Tsuchida, Jun; Niwa, Takako; Suzuki, Takashi; Ito, Mutsumi; Yamada, Shinya; Watanabe, Tokiko; Kiso, Maki; Negishi, Hideo; Temizoz, Burcu; Ishigaki, Hirohito; Kitagawa, Yoshinori; Nguyen, Cong Thanh; Itoh, Yasushi; Takeshita, Fumihiko; Kawaoka, Yoshihiro; Ishii, Ken J.
title: Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain
date: 2021-03-04
journal: bioRxiv
DOI: 10.1101/2021.03.04.433852
sha: ce5e376d39aa832db965c21aaa2b37e8d007729b
doc_id: 921647
cord_uid: o7b76fqc

In 2020, two mRNA-based vaccines, encoding the full length of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, have been introduced for control of the coronavirus disease (COVID-19) pandemic1,2. However, reactogenicity, such as fever, caused by innate immune responses to the vaccine formulation remains to be improved. Here, we optimized a lipid nanoparticle (LNP)-based mRNA vaccine candidate, encoding the SARS-CoV-2 spike protein receptor-binding domain (LNP-mRNA-RBD), which showed improved immunogenicity by removing reactogenic materials from the vaccine formulation and protective potential against SARS-CoV-2 infection in cynomolgus macaques. LNP-mRNA-RBD induced robust antigen-specific B cells and follicular helper T cells in the BALB/c strain but not in the C57BL/6 strain; the two strains have contrasting abilities to induce type I interferon production by dendritic cells. Removal of reactogenic materials from original synthesized mRNA by HPLC reduced type I interferon (IFN) production by dendritic cells, which improved immunogenicity. Immunization of cynomolgus macaques with an LNP encapsulating HPLC-purified mRNA induced robust anti-RBD IgG in the plasma and in various mucosal areas, including airways, thereby conferring protection against SARS-CoV-2 infection. Therefore, fine-tuning the balance between the immunogenic and reactogenic activity of mRNA-based vaccine formulations may offer safer and more efficacious outcomes.

Wuhan, China, in December 2019 7 . Two mRNA vaccines encoding the full-length spike 66 protein of SARS-CoV-2 have undergone Phase I-II-III trials, which were completed in 67 nine months and approved by regulatory authorities in various countries as well as the 68 WHO 1, 2, [8] [9] [10] . The results of their initial phase I-II clinical trials suggest that in both 69 younger and older adults, the two vaccine candidates elicited similar dose-dependent 70 SARS-CoV-2-neutralizing geometric mean titers, which were equivalent to that of a 71 panel of SARS-CoV-2 convalescent serum samples 9,10 . It is worth noting that an mRNA 72 vaccine (BNT162b2) encoding the full length of the SARS-CoV-2 spike protein was 73 associated with a lower incidence and severity of systemic reactions than another 74 mRNA vaccine encoding the RBD of spike protein (BNT162b1), particularly in older 75 adults 10 . A few scientific explanations have been offered: one is the amount of mRNA in 76 the RBD-mRNA vaccine, whose molar ratio is five times more than that of the 77 full-length mRNA vaccine due to an RNA length shorter by 1/5 at the same dose. 78

Although each RNA modification in the in vitro translated (IVT) mRNA to avoid innate 79 immune recognition was made, the number or position of the modified nucleoside of the 80 mRNAs may alter their immunostimulatory activity, acting as an endogenous adjuvant. 81

Here, we optimized an mRNA vaccine candidate encoding SARS-CoV-2 spike protein 82 RBD (319-541 aa) encapsulated in lipid nanoparticles (LNP-mRNA-RBD). 83

To date, a mouse model using the BALB/c strain has been commonly 84 used 6,11,12 , except for one study where C57BL/6 mice were immunized with 85 LNP-mRNA encoding SARS-CoV-2 RBD, resulting in antigen-specific germinal center 86

First, we immunized 6-8-week-old female mice of either the C57BL/6 or 88 BALB/c strains intramuscularly with 3 g of LNP-mRNA-RBD on days 0 and 14. 89

Unexpectedly, after two intramuscular immunizations, LNP-mRNA-RBD induced 90 significantly higher anti-RBD antibody responses in BALB/c mice but not in C57BL/6 91 mice in this study (Fig. 1a, Extended Fig 1) . To understand why LNP-mRNA-RBD 92 immunogenicity for antigen-specific B cell responses was different among mouse 93 strains, we further examined whether LNP-mRNA-RBD induces TFH and GC B cells 94 collected from the draining popliteal lymph nodes (pLN) and analyzed by flow 95 cytometry (Extended data Fig. 2 ). In correlation with serum antibody responses, the 96 frequency (%) of both TFH (CD4 + CD185 + PD-1 + cells) and GC B cells mice than that in C57BL/6 mice ( Fig. 1b-e) after LNP-mRNA-RBD immunization. 99

To further evaluate antigen-specific CD8 + and other CD4 + T cells induced by 100 LNP-mRNA-RBD, we synthesized 128 peptides, consisting of a 20-aa sequence of 101 difference in reactogenicity remains unclear, but the authors considered that 132 immunostimulatory activity of the mRNA in LNP formulation might be attributed to its 133 reactogenicity 10 . 134

In order to translate our findings from mice to humans, we then examined 135 whether LNP-mRNA-RBD triggers type I IFN production from human PBMCs. When 136 mixed with LNP-mRNA-RBD in vitro, PBMCs from three healthy humans produced a 137 higher amount of IFN-α than that induced by LNP-mRNA-Full (Fig. 2a) . We then 138 performed a similar experiment using mouse bone marrow-derived dendritic cells 139 (BM-DCs) from either C57BL/6 or BALB/c mice. Surprisingly, a high level of IFN-α 140 was observed upon culture with LNP-mRNA-full or LNP-mRNA-RBD in C57BL/6 141 mice, but very low or no IFN-α production was observed in BALB/c mice (Fig. 2b) . 142 LNP-mRNA products usually contain undesirable RNA, such as dsRNA as TLR3 143 ligand 22 , produced during the manufacturing process, which might affect innate immune 144 activation. To remove such RNA byproducts, we performed HPLC purification (data 145 not shown) and then the resultant mRNA containing the active ingredient was 146 encapsulated in LNP [RBD (HPLC)]. RBD (HPLC) showed significantly less potential 147 in production of type I IFN from both human PBMCs and GM-DCs ( Fig. 2a and b) . In 148 order to examine the immunogenicity, C57BL/6 or BALB/c mice were administered 149 with RBD (HPLC) or LNP-mRNA-RBD. Of interest, RBD (HPLC) showed 150 significantly higher levels of the RBD-specific B cell response than LNP-mRNA-RBD, 151 including serum IgG1, IgG2, and total IgG in both BALB/c and C57BL/6 mice ( Fig. 2c  152 and Extended Fig. 6a ). In particular, RBD (HPLC) induced significantly higher 153 number of GC B cells in the draining lymph nodes of the C57BL/6 mice than 154 LNP-mRNA-RBD ( Fig. 2d and e) . In addition to antibody responses, effects of 155 RNA-purification on antigen-specific T cell responses were further examined. RBD 156 (HPLC) induced higher frequency of the RBD-specific polyfunctional CD8 + and CD4 + 157 T cells that produced significantly more IFN-γ and other type-1 cytokines, but not 158 type-2 cytokines such as IL-13, in response to peptide pools 3 or 4 re-stimulation than 159 LNP-mRNA-RBD ( Fig. 2f-i, and Extended Fig. 6b-e, 7, 8) . 160

To further translate these findings to a more relevant pre-clinical evaluation of 161 RBD (HPLC), non-human primates (NHPs), cynomolgus macaques, were chosen for 162 further study. In this study, we immunized four macaques intramuscularly with RBD (HPLC) induced an anti-RBD-specific antibody, and the second immunization enhanced 165 these responses (Fig. 3b) . Neutralizing antibodies were also induced by RBD (HPLC) 166 vaccination (Fig. 3c) . We further examined antigen-specific antibody responses in swab 167 samples. Interestingly, following intramuscular immunization, levels of RBD-specific 168

IgG in the swab samples from conjunctiva, nasal cavity, oral cavity, trachea, and rectum 169 were significantly higher in RBD (HPLC) group than in the mock group (Fig. 3d) . 170

Individual macaques administered with RBD (HPLC) showed drastically 171 lower RNA levels of SARS-CoV-2 ( Fig. 4a) and infectious virus (Fig. 4b) in the swab 172 at day 1 post-infection than those administered with mock. Viral RNA levels in the 173 trachea, bronchus, and lung were lower in vaccinated macaques at day 7 ( Fig. 4c and 174 Extended Fig. 9 ). All mock-administered macaques manifested fever and pneumonia 175 after viral infection, which were not observed in immunized macaques (Extended thickening, and viral protein in macaques administered with mock but not in those 180 administered with RBD (HPLC) ( Fig. 4d and 4e) . Accordingly, histological scores of 181 the lung in macaques administered with RBD (HPLC) were lower than those 182 administered with mock ( Fig. 4f) . Of importance, intramuscular administration with 183 RBD (HPLC) induced the development of bronchus-associated lymphoid tissue (BALT) 184 ( Fig. 4d) , although intramuscular immunization induced RBD-specific IgG, but not IgA, 185 in swab samples without intranasal and intratracheal virus challenge (Fig. 3b) . 186

Interestingly, the IgG titer was slightly reduced or similar after viral challenge (Fig. 3d) . 187

These results suggest that the induced antibody in the mucosa through BALT formation, 188 such as the nasal and trachea mucosa, might capture and neutralize SARS-CoV-2, 189 resulting in the reduction of viral RNA and infective virus in the swab at day 1 190 post-challenge. 191 In this study, we evaluated the nonclinical efficacy of LNP-mRNA vaccine 192 candidates targeting SARS-CoV-2 RBD. First, LNP-mRNA-RBD showed higher 193 immunogenicity only in BALB/c mice than in C57BL/6 mice (Fig. 1a) . We initially 194 interpreted the data by suggesting the less T cell epitopes of the RBD in C57/BL6 as the 195 cause. In fact, CD4 Tfh induction was lower in C57BL/6 mice than that of BALB/c BioNTech/Pfizer showed that an mRNA vaccine that encoded the RBD resulted in a 198 high titer of RBD-specific IgG and neutralizing antibodies in humans and monkeys. 199

These results suggest that RBD does contain T cell epitopes, at least in primates 6,10 . 200 These data led us to hypothesize that the difference in vaccine-induced adaptive 201 immune responses is altered by the species-or strain-specific innate immune responses 202 to the LNP-mRNA formulation, which is shown to interfere with the mRNA expression 203 of the protein antigen of interest, thereby reducing immunogenicity and efficacy 16 . Our 204 data strongly suggest that optimization of purification and formulation of LNP-mRNA 205 contributes to improvement of LNP-mRNA immunogenicity with less reactogenicity. 206

It is of note that macaques administered with LNP-mRNA targeting RBD 207 acquired significantly high levels of protective IgG specific to SARS-CoV-2 in mucosal 208 swab samples from conjunctiva, oral cavity, nasal cavity, trachea, bronchus, and rectum 209 lower airways and showed that the IgG level in the BALF was higher than the IgA level 213 after the infection, although whether the vaccine antigen-specific IgG was induced 214 before the virus challenge was not shown 23 . Although HPLC-purified 215 LNP-mRNA-RBD elicited RBD-specific mucosal IgG, no RBD-specific IgA was 216 detected (data not shown), indicating that the mucosal IgG through BALT formation or 217 leaked from the blood circulation, which may be critical for the protective efficacy of 218 LNP-mRNA-RBD. Further detailed analyses are needed to clarify whether LNP-mRNA 219 induces unique and/or specific immune responses including IgG secretion in the mucosa 220 after intramuscular vaccination. 221

Based on our results obtained in murine and NHP models, reduction of 222 reactogenicity without losing immunogenicity, in other words, fine-tuning of the 223 balance between endogenous adjuvant activity and antigen translation efficiency of 224 LNP-mRNA, may provide a means towards better efficacy and safety and will also be 225 crucial for the development of anti-SARS-CoV2 vaccines in the near future. were measured using ELISA. (g-h) Percentages of cytokine-producing CD8 + and CD4 + 240 T cells after stimulation with pools 2, 3, and 4 for 6 h with protein transport inhibitor are 241

shown in a pie chart. 3 + : IFN-γ + IL-2 + TNF-α + , 2 + : IFN-γ + IL-2 + , IFN-γ + TNF-α + , and 242 IL-2 + TNF-α + , 1 + : IFN-γ + , IL-2 + , and TNF-α + . N = 4-5 mice per group, mean ± SEM, *p 243 were gated as CD185 + PD-1 + CD3ε + CD4 + T cells. (f and g) Cells were harvested from level in the culture supernatant was measured using ELISA. Percentages of 261 cytokine-producing CD8 + and CD4 + T cells after stimulation of peptide pools 3 and 4 262 for 6 h with protein transport inhibitors are shown in a pie chart. 3 + : IFN-γ + IL-2 + TNF-α + , 263 2 + : IFN-γ + IL-2 + , IFN-γ + TNF-α + , and IL-2 + TNF-α + , 1 + : IFN-γ + , IL-2 + , and TNF-α + . Six to eight week-old C57BL/6 and BALB/c mice were purchased from CLEA, Japan. 366

The mice were maintained under specific pathogen-free conditions. All mouse studies 367 were approved by the Animal Experiment Committee of the Institute of Medical 368

Science, University of Tokyo. 369 370

Seven to ten-year-old female cynomolgus macaques born at Shiga University of 372

Medical Science and originating from Philippines, Vietnam, and China were used. All 373 procedures were performed under ketamine and xylazine anesthesia, and all efforts were 374 made to minimize suffering. Food pellets of CMK-2 (CLEA Japan, Inc., Tokyo, Japan) 375

were provided once a day after recovery from anesthesia and drinking water was 376 available ad libitum. The animals were singly housed in cages under controlled 377 conditions of light (12-h light/12-h dark cycle, lights on at 8:00 a.m.). The macaques 378

were challenged with the SARS-CoV-2 (2 × 10 7 PFU/7 mL HBSS), which was 379 inoculated into the conjunctiva (0.05 mL × 2), nostrils (0.5 mL × 2), oral cavity (0.9 380 mL), and trachea (5 mL (under or over 50% of the section area)). The average score of 8 sections was calculated 507 for each macaque, and the mean score of the two pathologists were defined as the 508 histological score. SARS-CoV-2 N antigen was detected by a monoclonal antibody 509 8G8A (Bioss Inc) and secondary antibody following antigen retrieval using autoclave in 510 pH 9 citrate buffer. 511 512

Two weeks before virus inoculation, two temperature data loggers (iButton, Maxim 514

Integrated, San Jose, CA) were implanted in the peritoneal cavity of each macaque 515 under ketamine/xylazine anesthesia followed by isoflurane inhalation to monitor body 516 temperature. 517 518

Chest X-ray radiographs were taken using the I-PACS system (Konica Minolta Inc., 520 Tokyo, Japan) and PX-20BT mini (Kenko Tokina Corporation, Tokyo, Japan). 521 522

Statistical significance (P < 0.05) between groups was determined using the 524

Mann-Whitney U test or ANOVA. 525

We thank Fusako Ikeda, Ryoko Suda, Yoko Watanabe, Naomi Sato, Naoko Kitagawa 528 and Hideaki Ishida for technical assistance. This study was supported by AMED under 529

Grant Number JP20fk0108113h0001 and JP20nk0101625h0201. 2020.2012.2011.421008, doi:10.1101/2020.12.11.421008 (2020) . 

Evaluation of the mRNA-1273 Vaccine against 616

SARS-CoV-2 in Nonhuman Primates

Syrian hamsters as a small animal model for 619

SARS-CoV-2 infection and countermeasure development

Neutralizing antibody-dependent and -independent 623 immune responses against SARS-CoV-2 in cynomolgus macaques